lunes, 16 de octubre de 2017

Live CE Webinar Sponsored by the Division of Drug Information - Drug Information Update




FDA’s Division of Drug Information (DDI) is presenting a series of continuing educationwebinars targeting the needs of all health care professionals.
DDI Webinar Series: An Overview of FDA Resources

Will be held on:

October 17, 2017


Time:  1:00 pm to 2:00 pm (EDT)
To register for the online meeting, please visit:
https://collaboration.fda.gov/ddi101717/event/registration.html
After registering, you will receive a calendar invitation with details on how to join the online meeting.

Activity Outline
Description: This series of educational webinars is designed to aid physicians, physician assistants, nurses, pharmacists, pharmacy technicians, students, and other health care professionals, to provide better patient care by knowing how to find relevant FDA regulatory information that will improve drug safety. This webinar will provide an orientation to drug information resources on the FDA website including drug shortages, recalls, adverse events reporting and drug labeling resources.

Series Objectives:
  • Explain how to utilize FDA’s drug information, medication safety resources, and regulatory guidance, to   improve delivery of patient care and optimize outcomes.
  • Describe and inform health care providers of recent labeling changes which would impact prescribing and medication management to optimize patient care.
References:
Session Learning Objectives: After completion of this activity, the participant will be able to:
  1. Identify FDA resources that contain information on drug safety issues
  2. Locate adverse event reporting information on FDA’s website
  3. Utilize drug information resources to stay informed on FDA actions, decisions and initiatives
Target Audience: This activity is intended for physicians, physician assistants, nurses, pharmacists, pharmacy technicians, students, and other health care professionals. 

Schedule:
1:00-2:00 pm – DDI Webinar Series: An Overview of FDA Resources presented by Heena Patel, PharmD.

Continuing Education
Accreditation:

In support of improving patient care, FDA Center for Drug Evaluation and Research is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.


CME
FDA Center for Drug Evaluation and Research designates this live activity for a maximum of 1 AMA PRA Category 1 Credit(s)™.  Physicians and physician assistants should claim only the credit commensurate with the extent of their participation in the activity.

CPE
This knowledge-based activity has been assigned ACPE Universal Activity Number 0601-0000-17-129-L04-P, and ACPE Universal Activity Number 0601-0000-17-130-L04-T, for 1 contact hour.
CNEFDA Center for Drug Evaluation and Research designates this activity for 1 contact hour.

Requirements for receiving CE Credit:
Physicians, physician assistants, nurses, pharmacists, and pharmacy technicians, and those claiming non-physician CME:  attendance is verified by Adobe Connect login or by a sign-in sheet, and completion of the final activity evaluation.  Final activity evaluations must be completed within two weeks after the activity.

Pharmacist and Pharmacy Technician participants:  partial credit cannot be awarded, therefore you must attend the entire activity to receive CPE credit. No exceptions.  Pharmacists and Pharmacy Technicians will need their NABP e-profile ID number as well as their DOB in MMDD format in order to claim CE credit. 


Statements of Credit:
Physicians and Nurses Statements of Credit for CE will be issued 10 weeks after the last session of this activity.  Pharmacists and Pharmacy Technicians should log into the CPE monitor 10 weeks after the last session of the activity to obtain their CE credit.  

Disclosure: 
Faculty: 
  • Heena Patel, PharmD, Drug Information Pharmacist, FDA/CDER/OCOMM/DDI - nothing to disclose
Planning Committee:
  • Kara Burke, PharmD, Consumer Safety Officer, FDA/CDER/OCOMM/DDI - nothing to disclose
  • Kimberly DeFronzo, RPh, MS, MBA, Consumer Safety Officer, FDA/CDER/OCOMM/DDI - nothing to disclose
  • Virginia Giroux, MSN, ARNP, CE Program Administrator, FDA/CDER/OEP/DLOD - nothing to disclose
  • Lesley Navin, RN, MSN, Consumer Safety Officer, FDA/CDER/OCOMM/DDI - nothing to disclose
  • Danielle Molnar, PharmD, Consumer Safety Officer, FDA/CDER/OCOMM/DDI - nothing to disclose
  • Edward Weinstein, MD, Medical Officer, FDA/CDER/OND/OAP/DAIP - discloses the following: “spouse receives salary from EndoCentre of Baltimore as an employee”
CE Consultation and Accreditation Team:
  • Justin Gorinson, CHES, ORISE Fellow, FDA/CDER/OEP/DLOD - nothing to disclose
  • Karen Zawalick, CE Consultation and Accreditation Team Leader, FDA/CDER/DLOD - nothing to disclose
Registration Fees and Refunds: Registration is complimentary therefore refunds are not applicable.

Requirements for Certificate of Completion (Non CE): 
Must attend 80% of the lectures (verified by a sign-in sheet). 
--------------
Please direct your comments or questions via email to DDIWebinars@fda.hhs.gov

FUTURE WEBINAR DATES:
November 21, 2017- DDI Webinar Series: Tainted Products Marketed as Dietary Supplements

No hay comentarios: